Researchers in Germany have found a new way to exploit the differences between cancer cells and normal cells that could lead to new treatments.
5 / 5 (2) |
0
|
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective ...
4.5 / 5 (2) |
0
|
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.
not rated yet |
0
Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and ...
not rated yet |
0
|
